Despite the slowdown over the past year, the biotech sector is well-positioned for long-term growth due to increasing demand for agro-based products, personalized healthcare, and synthetic biology solutions. Additionally, government initiatives and growing healthcare needs reinforce its promising outlook.
Amid this backdrop, it could be wise to buy fundamentally strong biotech stocks Gilead Sciences, Inc. (GILD) and Jazz Pharmaceuticals plc (JAZZ). On the other hand, it could be wise to avoid Bionano Genomics, Inc. (BNGO), given its weak fundamentals and poor growth prospects.
